ALG-097558
- Generic Name
- ALG-097558
Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 51
- Registration Number
- NCT06945276
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06698549
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Genesis Clinical Trials, Tampa, Florida, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Hepatic Impairment and in Healthy Subjects with Normal Hepatic Function
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT06568861
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Drug: PlaceboDrug: ALG-097558 in solution formulationDrug: ALG-097558 in tablet formulation
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT05840952
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
AGILE (Early Phase Platform Trial for COVID-19)
Phase 1
Active, not recruiting
- Conditions
- Covid19
- Interventions
- Drug: MolnupiravirDrug: NHS standard of care as per COVID-19 treatment guidelinesDrug: Paxlovid
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 600
- Registration Number
- NCT04746183
- Locations
- 🇬🇧
Manchester University NHS Foundation Trust, Manchester, United Kingdom
🇿🇦Desmond Tutu Health Foundation, Cape Town, South Africa
🇿🇦Ezintsha, Johannesburg, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath